|
US7056916B2
(en)
|
2002-11-15 |
2006-06-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Medicaments for the treatment of chronic obstructive pulmonary disease
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
DE102004019539A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
|
|
DK2422786T3
(da)
*
|
2004-04-22 |
2014-11-17 |
Boehringer Ingelheim Int |
Nye lægemiddelkombinationer til behandling af luftvejssygdomme
|
|
JP2007537187A
(ja)
*
|
2004-05-13 |
2007-12-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
|
|
DE102004024451A1
(de)
*
|
2004-05-14 |
2005-12-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
|
|
US7745621B2
(en)
|
2004-05-14 |
2010-06-29 |
Boehringer Ingelheim International Gmbh |
Long acting bronchodilators for the treatment of respiratory diseases
|
|
DE102004024453A1
(de)
*
|
2004-05-14 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
|
|
US7220742B2
(en)
|
2004-05-14 |
2007-05-22 |
Boehringer Ingelheim International Gmbh |
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
|
|
US20050256115A1
(en)
*
|
2004-05-14 |
2005-11-17 |
Boehringer Ingelheim International Gmbh |
Aerosol formulation for the inhalation of beta-agonists
|
|
DE102004024454A1
(de)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
DE102004024452A1
(de)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Aerosolformulierung für die Inhalation von Betaagonisten
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
DE102004045648A1
(de)
*
|
2004-09-21 |
2006-03-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Betamimetika zur Behandlung von Atemwegserkrankungen
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
DE102005007654A1
(de)
*
|
2005-02-19 |
2006-08-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
DE102005030733A1
(de)
*
|
2005-07-01 |
2007-01-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
|
|
EP1924553A1
(en)
|
2005-08-08 |
2008-05-28 |
Argenta Discovery Limited |
Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
|
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
|
BRPI0614410A2
(pt)
|
2005-08-15 |
2011-03-29 |
Boehringer Ingelheim Int |
processo para preparação de betamiméticos
|
|
US20070088030A1
(en)
*
|
2005-10-10 |
2007-04-19 |
Barbara Niklaus-Humke |
Aerosol formulations for the inhalation of beta-agonists
|
|
TWI396541B
(zh)
|
2005-10-10 |
2013-05-21 |
Boehringer Ingelheim Int |
用於治療呼吸疾病之新穎藥物組合
|
|
EP1957530A2
(en)
|
2005-10-21 |
2008-08-20 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
|
CA2627726A1
(en)
*
|
2005-11-09 |
2007-05-18 |
Boehringer Ingelheim International Gmbh |
Aerosolformulation for inhalation
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
JP2009526817A
(ja)
*
|
2006-02-16 |
2009-07-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
呼吸器疾患の治療用医薬組成物
|
|
PE20080142A1
(es)
*
|
2006-03-15 |
2008-04-14 |
Boehringer Ingelheim Int |
Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
|
|
SI2013211T1
(sl)
|
2006-04-21 |
2012-07-31 |
Novartis Ag |
Purinski derivati za uporabo kot agonisti receptorja adenozina A A
|
|
WO2008017638A1
(de)
*
|
2006-08-07 |
2008-02-14 |
Boehringer Ingelheim International Gmbh |
Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
|
|
UY30543A1
(es)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
Formulacion de aerosol para la inhalacion de beta- agonistas
|
|
UY30542A1
(es)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
Formulacion de aerosol para la inhalacion de agonistas beta
|
|
MX2009003185A
(es)
|
2006-09-29 |
2009-04-03 |
Novartis Ag |
Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
|
|
CN101522682A
(zh)
|
2006-10-30 |
2009-09-02 |
诺瓦提斯公司 |
作为抗炎剂的杂环化合物
|
|
PL2104535T3
(pl)
|
2007-01-10 |
2011-05-31 |
Irm Llc |
Związki i kompozycje jako inhibitory proteazy aktywujące kanały
|
|
AR065017A1
(es)
*
|
2007-01-25 |
2009-05-13 |
Boehringer Ingelheim Int |
Procedimiento para la preparacion de betamimeticos
|
|
AU2008248598B2
(en)
|
2007-05-07 |
2011-11-17 |
Novartis Ag |
Organic compounds
|
|
PL2444120T3
(pl)
|
2007-12-10 |
2018-02-28 |
Novartis Ag |
Spirocyklicze analogi amiloridu jako blokery ENac
|
|
JP5584138B2
(ja)
|
2008-01-11 |
2014-09-03 |
ノバルティス アーゲー |
キナーゼ阻害剤としてのピリミジン類
|
|
KR20110040818A
(ko)
|
2008-06-10 |
2011-04-20 |
노파르티스 아게 |
상피 나트륨 채널 차단제로서의 피라진 유도체
|
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
|
JP5555255B2
(ja)
|
2008-12-30 |
2014-07-23 |
プルマゲン セラピューティクス(インフラメーション)リミテッド |
呼吸器疾患の治療のためのスルホンアミド化合物
|
|
PL2391366T3
(pl)
|
2009-01-29 |
2013-04-30 |
Novartis Ag |
Podstawione benzimidazole do leczenia gwiaździaków
|
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
KR101721280B1
(ko)
|
2009-08-17 |
2017-03-29 |
인텔리카인, 엘엘씨 |
헤테로사이클릭 화합물 및 이의 용도
|
|
EP2490687A1
(en)
|
2009-10-22 |
2012-08-29 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
MX390695B
(es)
*
|
2010-09-21 |
2025-03-21 |
Intekrin Therapeutics Inc |
Composiciones farmaceuticas solidas antidiabeticas
|
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
|
GEP20156285B
(en)
|
2011-02-25 |
2015-05-11 |
Aierem Elelsi |
Compounds and compositions as trk inhibitors
|
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
|
EP2755976B1
(en)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
ES2882807T3
(es)
|
2011-09-16 |
2021-12-02 |
Novartis Ag |
Heterociclil carboxamidas N-sustituidas
|
|
ES2558457T3
(es)
|
2011-09-16 |
2016-02-04 |
Novartis Ag |
Compuestos heterocíclicos para el tratamiento de fibrosis quística
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
EP2793893A4
(en)
|
2011-11-23 |
2015-07-08 |
Intellikine Llc |
IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
CN110507654A
(zh)
|
2012-04-03 |
2019-11-29 |
诺华有限公司 |
有酪氨酸激酶抑制剂的组合产品和其应用
|
|
EP2906218B1
(en)
|
2012-10-09 |
2016-12-14 |
Boehringer Ingelheim International GmbH |
Beta-2-adrenoceptor agonist for the treatment of cough
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
US10112926B2
(en)
|
2014-04-24 |
2018-10-30 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
EA033571B1
(ru)
|
2014-04-24 |
2019-11-06 |
Novartis Ag |
Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
|
|
CA2945212A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
BR112017001695A2
(pt)
|
2014-07-31 |
2017-11-21 |
Novartis Ag |
terapia de combinação
|
|
US20200069679A1
(en)
|
2016-12-12 |
2020-03-05 |
Boehringer Ingelheim International Gmbh |
Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
|
|
WO2018114887A1
(en)
|
2016-12-20 |
2018-06-28 |
Laboratorios Lesvi, S.L. |
Improved process for the manufacture of r-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
|
|
CN108997248B
(zh)
*
|
2018-08-06 |
2023-08-01 |
上海方予健康医药科技有限公司 |
盐酸奥达特罗晶型b及其制备方法
|
|
CN109096218B
(zh)
*
|
2018-08-06 |
2020-10-27 |
上海方予健康医药科技有限公司 |
盐酸奥达特罗晶型a及其制备方法
|
|
MX2021015133A
(es)
|
2019-06-10 |
2022-01-24 |
Novartis Ag |
Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
|
|
PE20220346A1
(es)
|
2019-08-28 |
2022-03-14 |
Novartis Ag |
Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
|
|
US11304897B2
(en)
|
2020-06-09 |
2022-04-19 |
Anovent Pharmaceutical (U.S.), Llc |
Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
|
|
US11331322B1
(en)
|
2021-09-15 |
2022-05-17 |
Santen Pharmaceutical Co., Ltd. |
Medicament for preventing and/or treating dry eye
|